Contents | 34 of 35

Clinical Trials to Clinical Use: Using Vision as a Model for Multiple Sclerosis and Beyond

Update Item Information
Title Journal of Neuro-Ophthalmology, September 2014, Volume 34, Issue 3
Date 2014-09
Language eng
Format application/pdf
Type Text
Publication Type Journal Article
Collection Neuro-Ophthalmology Virtual Education Library: Journal of Neuro-Ophthalmology Archives: https://novel.utah.edu/jno/
Publisher Lippincott, Williams & Wilkins
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah
Rights Management © North American Neuro-Ophthalmology Society
ARK ark:/87278/s6kh3tdd
Setname ehsl_novel_jno
ID 227634
Reference URL https://collections.lib.utah.edu/ark:/87278/s6kh3tdd

Page Metadata

Title Clinical Trials to Clinical Use: Using Vision as a Model for Multiple Sclerosis and Beyond
Creator Laura J. Balcer, MD, Professor, Department of Neurology, NYU Langone
Affiliation Departments of Neurology and Population Health, New York University School of Medicine, New York, New York
Abstract Optical coherence tomography (OCT) has made possible the structure-function correlations that uniquely characterize the afferent visual pathway as a model for understanding multiple sclerosis (MS) and for developing new treatments. During the past decade, OCT measures of retinal nerve fiber layer (RNFL) and ganglion cell/inner plexiform layer (GCL + IPL) thickness have evolved from being a means to validate visual function tests, such as low-contrast letter acuity, to provide a window on the axonal and neuronal loss that are now widely recognized as contributors to permanent visual dysfunction in MS. Although acute optic neuritis (ON) leads to thinning of the RNFL by 20%-40% within 3 months after a single episode, thinning of the RNFL and GCL + IPL occur over time in MS eyes even in the absence of an acute ON history. As such, OCT and its functional and patient-reported correlates of low-contrast acuity and vision-specific quality of life (QOL) have now been incorporated into MS clinical trials. Results of an ongoing, phase 2 trial of a remyelinating agent that uses acute ON as a model for assessing therapeutic efficacy will define even further the important role for OCT in documenting structural changes as we move forward from clinical trials to clinical use.
Subject Clinical Trials as Topic; History, 20th Century; History, 21st Century; Humans; Multiple Sclerosis; Optic Neuritis; Quality of Life; Tomography, Optical Coherence; Vision Disorders; Visual Pathways
OCR Text Show
Format application/pdf
Publication Type Journal Article
Collection Neuro-Ophthalmology Virtual Education Library: Journal of Neuro-Ophthalmology Archives: https://novel.utah.edu/jno/
Publisher Lippincott, Williams & Wilkins
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah
Rights Management © North American Neuro-Ophthalmology Society
Setname ehsl_novel_jno
ID 227632
Reference URL https://collections.lib.utah.edu/ark:/87278/s6kh3tdd/227632
Back to Search Results